82 Biosimilars Approved and Your Reference Product Is Next
The FDA has now approved 82 biosimilars, with the first insulin aspart biosimilar clearing in early 2026. A $230 billion patent cliff is creating the largest biosimilar window in pharmaceutical history, yet biosimilar formulation remains one of the hardest problems in the industry. You must reverse-engineer a reference product's formulation while navigating composition, process, and method-of-use patents. The companies that can rapidly deconstruct reference formulations, identify patent white space, and design bioequivalent alternatives will capture disproportionate value.
$230 Billion in Biologic Revenue Hits the Cliff
The FDA approved its 82nd biosimilar on January 15, 2026: Filkri (filgrastim-laha), a leukocyte growth factor biosimilar to Neupogen. The number matters because of what it says about the pace of approvals. In 2024 alone, the agency approved 19 biosimilars, the highest single-year count in the program's history. Average review timelines have fallen from 798 days to 364 days, a 54% reduction in just four years. And the FDA plans to finalize guidance in the first half of 2026 that would make all non-vaccine biosimilars eligible for interchangeability designation, eliminating the clinical switching studies that have historically slowed approvals.
Between 2026 and 2030, roughly 190 drugs, including 69 blockbusters, will lose market exclusivity, putting $236 billion to $400 billion in annual branded drug sales at risk. Among them: Keytruda ($29 billion in 2024 revenue, patent expiry 2028), Farxiga ($7.7 billion, 2026), Ibrance ($6.4 billion, 2027), and Enbrel ($5.4 billion, 2028). The top 20 drugs heading for the patent cliff accounted for a combined $176.4 billion in 2024 sales.
Yet 90% of the 118 biologics losing patent protection by 2034 have no biosimilar in the development pipeline. Biosimilar formulation is reverse engineering a 150,000-dalton protein whose three-dimensional structure, biological activity, and immunogenicity profile are all direct consequences of a manufacturing process that you do not control and, in most cases, do not fully understand. The companies that can rapidly deconstruct reference formulations, map patent white space, and design bioequivalent alternatives will capture the bulk of this opportunity.
FDA-approved biosimilars as of January 2026. Since the first U.S. biosimilar launched in 2015, the healthcare system has saved nearly $36 billion, with $20.2 billion in savings in 2024 alone. IQVIA estimates that a fully competitive biosimilar market could save the U.S. an additional $189 billion over the next decade.
Source: IQVIA Institute for Human Data Science, 2025The Humira Aftermath: What Happened and What It Predicts
The adalimumab biosimilar story is the most instructive case study for the wave now arriving. At its peak, Humira generated over $21 billion in annual U.S. sales. Then the biosimilars arrived.
AbbVie's net sales for adalimumab dropped 45% in a single quarter, from $5 billion in Q4 2022 to $2.8 billion in Q4 2023, immediately after biosimilar entry. Net price per prescription fell 43%, from $5,007 to $2,837, in the same period. Humira's global market, estimated at $10.34 billion in 2024, is projected to decline to $4.11 billion by 2030, a CAGR of negative 11.29%. Seven biosimilars now carry interchangeable designations, and major PBMs (CVS Caremark, Evernorth/Express Scripts, Optum Rx) are actively recommending biosimilar-first or biosimilar-only formulary positions.
The pattern is consistent: once biosimilars enter a therapeutic category with clinical confidence and payer support, the reference product's revenue erosion is rapid and irreversible. Every biologic sponsor sitting on a blockbuster with patents expiring in the next five years should be studying these curves, and every biosimilar developer should be asking whether their formulation capabilities are fast enough to win first-mover advantage before the window narrows.
Product | Reference Revenue Impact | Biosimilar Uptake | Timeline |
|---|---|---|---|
Humira (adalimumab) | 45% sales drop in one quarter | 7 interchangeable biosimilars | Q4 2022 to Q4 2023 |
Bevacizumab | Near-complete market shift | 90% biosimilar share | Established oncology market |
Stelara (ustekinumab) | Rapid price collapse | 80-90% discounts from entrants | 2025 biosimilar launch |
Insulin Glargine | Moderate revenue erosion | Moderate uptake | Gradual substitution |
In oncology, uptake has been steeper still. Stelara (ustekinumab) biosimilar entry in 2025 confirmed the pattern at an even faster pace, with eight FDA-approved biosimilars launched and Wezlana carrying interchangeability designation from day one. New entrants offered discounts of 80-90% relative to Stelara's wholesale acquisition cost.
Source: FDA Biosimilar Product Information, 2025
Keytruda: The $29 Billion Target
The largest single target in the coming patent cliff is Merck's Keytruda (pembrolizumab), with $29 billion in 2024 revenue and a core patent expiry in 2028. Multiple companies are already in clinical-stage development. Samsung Bioepis initiated a Phase 3 trial for SB27 in metastatic non-squamous NSCLC in April 2024, with estimated primary completion in September 2025 and a potential 351(k) filing in Q1-Q2 2026. Amgen's ABP-234 has completed enrollment in comparative clinical studies.
Merck, meanwhile, is building its defenses. The FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection on September 19, 2025, converting a 30-minute IV infusion into a one-minute subcutaneous administration. The study showed a 45% overall response rate in NSCLC versus 42% for IV Keytruda, giving Merck clinical differentiation and additional patent protection against biosimilar competitors limited to IV delivery. Analysts project Keytruda Qlex could bring in $8-12 billion in incremental revenue through 2030.
Originators are deploying new formulations, delivery routes, and device patents while biosimilar developers try to file before those strategies block them out. The first pembrolizumab biosimilar to reach the market could take billions in revenue; the third or fourth entrant will compete on price alone.
Biosimilar vs. Generic: Orders of Magnitude Apart
The casual comparison between biosimilar development and generic drug development obscures a difference of several orders of magnitude in complexity. A small-molecule generic like aspirin has a molecular weight of roughly 180 daltons, costs $1-2 million to develop, and takes approximately two years to reach market. A monoclonal antibody biosimilar has a molecular weight of approximately 150,000 daltons, costs $100-250 million to develop, and takes 5-9 years.
The fundamental challenge is captured in the axiom that "the process is the product." A biologic's three-dimensional folding, post-translational modifications, aggregate profile, and immunogenic potential are all direct consequences of the proprietary manufacturing process: the cell line, the culture media, the purification steps, the fill-finish conditions. Biosimilar developers have little to no visibility into that process. They are reverse-engineering a product whose critical quality attributes emerge from conditions they cannot observe.
Protein Aggregation
During manufacturing, protein unfolding exposes hydrophobic patches that drive aggregation under shear, thermal, chemical, and freeze-thaw stresses. Significant aggregate populations can elicit immunogenic responses, ranging from reduced efficacy to life-threatening adverse reactions.
Immunogenicity Risk
Glycosylation
The type, number, and location of sugar molecules attached to the protein backbone affect biological function, stability, immunogenicity, half-life, and efficacy. These variables are process-dependent, proprietary, and extraordinarily sensitive to manufacturing conditions.
Hardest to Match
Buffer Systems & High Concentration
Buffer-free, high-concentration systems using protein self-buffering improve patient comfort and stability. For subcutaneous delivery of high-concentration mAbs, viscosity management becomes a primary constraint.
Regulatory Deviation Allowed
Device & Delivery
Originators file extensively on auto-injector mechanisms, prefilled syringe designs, needle guards, and device ergonomics. A biosimilar developer can create a perfectly comparable drug product only to discover they are blocked by dozens of device patents.
Patent Blocking Risk
The Patent Dance and the Thicket
The Biologics Price Competition and Innovation Act (BPCIA) established the abbreviated Biologics License Application (aBLA) pathway under Section 351(k) of the Public Health Service Act. The statute includes a pre-litigation information exchange between the biosimilar applicant and the reference product sponsor known colloquially as the "patent dance," a multi-step process in which the parties identify relevant patents, negotiate which to litigate first, and proceed through waves of patent litigation before the biosimilar can launch.
Reference product sponsors construct "patent thickets," dense webs of dozens, sometimes hundreds, of patents covering composition of matter, formulation (buffer systems, excipients, concentrations), manufacturing processes (cell line specifics, purification steps), methods of use (specific indications, dosing regimens), and delivery devices. The strategic objective is to create so many potential infringement vectors that biosimilar developers face years of litigation risk even after achieving analytical and clinical biosimilarity.
For biosimilar developers, formulation freedom-to-operate analysis cannot be an afterthought. It must be integrated into formulation design from the earliest stages. Every buffer choice, excipient selection, and concentration decision must be evaluated for its impact on product quality and for its position relative to the reference product's patent estate. The companies that treat FTO analysis and formulation development as parallel, integrated workstreams rather than sequential activities will reach market faster and with fewer litigation surprises.
351(k) Pathway
The abbreviated Biologics License Application pathway under the BPCIA. The FDA's planned 2026 guidance would make all non-vaccine biosimilars eligible for interchangeability designation based on analytical comparability, pharmacokinetic assessments, and immunogenicity data, without dedicated clinical switching studies.
$36B
Cumulative Healthcare Savings Since 2015
Interchangeability Designation
Enables automatic pharmacy-level substitution without prescriber intervention, accelerating market uptake considerably. The shift changes the competitive calculus: if clinical switching studies are no longer required, the bottleneck moves upstream to analytical characterization and formulation design.
$189B
Projected Additional Savings (Next Decade)
The M&A Response
The patent cliff is driving record M&A activity. The EY Firepower Report 2026 revealed that the life sciences industry has a record $2.1 trillion in available acquisition capacity, with the top 25 biopharma companies seeing a 23% jump to $1.6 trillion year-over-year. Global life sciences M&A investment totaled $240 billion in 2025, an 81% increase over 2024. Deal volume surged 82% in early 2026, with average deal sizes more than doubling to $2.1 billion.
EY projects a growth gap of $100 billion by 2028, expanding to $370 billion by 2032, as blockbuster products lose exclusivity. Companies like Merck ($10 billion for Verona Pharma) and Sanofi ($9.5 billion for Blueprint Medicines) are acquiring validated late-stage assets to fill the revenue holes that biosimilar competition will create.
For formulation-focused organizations, this M&A environment cuts two ways. Companies with demonstrated biosimilar formulation capability are acquisition targets. Those without it are scrambling to buy what they cannot build in time.
Pipeline Scale
$11.9B
Sandoz projected FY2026 revenue
$3B
Amgen biosimilar sales (37% growth, 2025)
28
Sandoz biosimilar molecules in pipeline
M&A Firepower
$2.1T
Industry acquisition capacity (2026)
81%
M&A investment increase (2025 vs 2024)
$370B
Projected growth gap by 2032
How DeepC Addresses the Biosimilar Formulation Challenge
Biosimilar formulation requires solving analytical, formulation, and IP problems simultaneously. Doing them sequentially is too slow to win first-filing position in any therapeutic category.
Reference Product Deconstruction
DeepC's platform provides immediate access to FDA Inactive Ingredient Database records, published analytical characterization studies, and patent filings that reveal manufacturing conditions and formulation strategies.
Patent Mapping
The FTO Agent maps the reference product sponsor's patent estate across all five vectors: composition of matter, formulation, process, method-of-use, and device patents, identifying design-around opportunities in real time.
Alternative Formulation Design
The Formulation Agent designs candidate biosimilar formulations that achieve analytical similarity while avoiding patent claims, evaluating buffer systems, surfactants, stabilizers, and concentration ranges for aggregation, viscosity, and stability impact.
Performance Matching
The Optimization Agent optimizes candidates against critical quality attributes: aggregate levels, charge variant distribution, thermal stability, and forced degradation profiles under ICH storage conditions.
IP Protection
Once a differentiated biosimilar formulation is identified, the FTO-WRITE Agent generates freedom-to-operate opinions and drafts patent claims to protect the novel formulation, buffer system, or process innovations. In a market where multiple companies race toward the same reference product, protecting your formulation IP is as important as designing it.
Strategic Implications
The patent cliff, regulatory change, and formulation technology advances together create a set of priorities for pharmaceutical companies:
1
Filing first pays disproportionately. Humira and Stelara data confirm that the first interchangeable biosimilar in a category captures the largest share. In the pembrolizumab race, the gap between a 2026 filing and a 2028 filing could be several billion dollars in cumulative revenue.
2
Analytical characterization replaces clinical switching studies.
The FDA's planned 2026 guidance means thorough analytical work, not switching trials, will determine interchangeability. Companies with strong analytical and formulation matching capabilities will reach that threshold faster and cheaper.
3
FTO analysis belongs in early formulation, not late stage.
Running FTO after formulation lock is the most common and expensive mistake in biosimilar development. Design-around opportunities found early save years of litigation risk. Found after Phase 3, they require reformulation, new stability data, and amended filings.
4
90% of at-risk biologics have no biosimilar pipeline.
These overlooked molecules represent a larger aggregate opportunity than the high-profile targets where multiple competitors are already in development, and they often have simpler patent situations.
5
Originator lifecycle strategies are already in motion.
Merck's Keytruda Qlex SC conversion, with new clinical data and additional patents, is a template other originators will copy. Biosimilar developers need to anticipate these moves and design formulations that compete with both the original product and its next-generation variants.
6
Integrated formulation-to-patent workflows win.
Companies that move from reference product analysis to patented biosimilar formulation in one workflow will outperform those running fragmented processes across multiple external partners.
The Bottom Line
"The global biosimilar market was $38.12 billion in 2025 and is projected at $122 billion by 2034. The $230 billion patent cliff is already underway. Biosimilar formulation remains one of the hardest problems in pharmaceutical development: reverse-engineering a complex protein, matching its quality attributes across dozens of parameters, inside a patent environment designed to prevent exactly that. The companies that compress this process from years to months will take the largest share."